 Phosphatidylinositol 3-Kinases
"Phosphatidylinositol 3-Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Phosphotransferases that catalyzes the conversion of 1-phosphatidylinositol to 1-phosphatidylinositol 3-phosphate. Many members of this enzyme class are involved in RECEPTOR MEDIATED SIGNAL TRANSDUCTION and regulation of vesicular transport with the cell. Phosphatidylinositol 3-Kinases have been classified both according to their substrate specificity and their mode of action within the cell.
| Descriptor ID |
D019869
|
| MeSH Number(s) |
D08.811.913.696.620.500
|
| Concept/Terms |
Phosphatidylinositol 3-Kinases- Phosphatidylinositol 3-Kinases
- Phosphatidylinositol 3 Kinases
- Phosphoinositide 3-Hydroxykinase
- PI 3-Kinase
- PtdIns 3-Kinases
- 3-Kinases, PtdIns
- PtdIns 3 Kinases
- PI-3K
- PI3 Kinases
- Kinases, PI3
- PI3-Kinase
- PtdIns 3-Kinase
- Phosphatidylinositol-3-OH Kinase
- PI-3 Kinase
|
Below are MeSH descriptors whose meaning is more general than "Phosphatidylinositol 3-Kinases".
Below are MeSH descriptors whose meaning is more specific than "Phosphatidylinositol 3-Kinases".
This graph shows the total number of publications written about "Phosphatidylinositol 3-Kinases" by people in this website by year, and whether "Phosphatidylinositol 3-Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 | | 1994 | 0 | 1 | 1 | | 1995 | 0 | 2 | 2 | | 1996 | 0 | 3 | 3 | | 1997 | 1 | 2 | 3 | | 1998 | 1 | 1 | 2 | | 1999 | 1 | 3 | 4 | | 2000 | 1 | 2 | 3 | | 2001 | 7 | 3 | 10 | | 2002 | 2 | 11 | 13 | | 2003 | 4 | 6 | 10 | | 2004 | 5 | 6 | 11 | | 2005 | 3 | 4 | 7 | | 2006 | 4 | 8 | 12 | | 2007 | 5 | 6 | 11 | | 2008 | 8 | 6 | 14 | | 2009 | 5 | 2 | 7 | | 2010 | 6 | 6 | 12 | | 2011 | 0 | 9 | 9 | | 2012 | 4 | 5 | 9 | | 2013 | 5 | 8 | 13 | | 2014 | 5 | 11 | 16 | | 2015 | 4 | 9 | 13 | | 2016 | 5 | 6 | 11 | | 2017 | 5 | 8 | 13 | | 2018 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Phosphatidylinositol 3-Kinases" by people in Profiles.
-
Cao Y, Liu H, Gao L, Lu L, Du L, Bai H, Li J, Said S, Wang XJ, Song J, Serkova N, Wei M, Xiao J, Lu SL. Cooperation Between Pten and Smad4 in Murine Salivary Gland Tumor Formation and Progression. Neoplasia. 2018 08; 20(8):764-774.
-
Ziemba BP, Falke JJ. A PKC-MARCKS-PI3K regulatory module links Ca2+ and PIP3 signals at the leading edge of polarized macrophages. PLoS One. 2018; 13(5):e0196678.
-
Buckles TC, Ziemba BP, Masson GR, Williams RL, Falke JJ. Single-Molecule Study Reveals How Receptor and Ras Synergistically Activate PI3Ka and PIP3 Signaling. Biophys J. 2017 Dec 05; 113(11):2396-2405.
-
Wainberg ZA, Alsina M, Soares HP, Braña I, Britten CD, Del Conte G, Ezeh P, Houk B, Kern KA, Leong S, Pathan N, Pierce KJ, Siu LL, Vermette J, Tabernero J. A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Target Oncol. 2017 Dec; 12(6):775-785.
-
Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6468-6477.
-
Williams MM, Vaught DB, Joly MM, Hicks DJ, Sanchez V, Owens P, Rahman B, Elion DL, Balko JM, Cook RS. ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation. Breast Cancer Res. 2017 Sep 08; 19(1):105.
-
Leong S, Moss RA, Bowles DW, Ware JA, Zhou J, Spoerke JM, Lackner MR, Shankar G, Schutzman JL, van der Noll R, Voest EE, Schellens JHM. A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors. Oncologist. 2017 12; 22(12):1491-1499.
-
Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, English I, Ho H, Pandya R, Bolosky WJ, Poon H, Deininger MW, Collins R, Swords RT, Watts J, Pollyea DA, Medeiros BC, Traer E, Tognon CE, Mori M, Druker BJ, Tyner JW. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proc Natl Acad Sci U S A. 2017 09 05; 114(36):E7554-E7563.
-
Bitler BG, Wu S, Park PH, Hai Y, Aird KM, Wang Y, Zhai Y, Kossenkov AV, Vara-Ailor A, Rauscher FJ, Zou W, Speicher DW, Huntsman DG, Conejo-Garcia JR, Cho KR, Christianson DW, Zhang R. ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nat Cell Biol. 2017 08; 19(8):962-973.
-
Imbert V, Nebout M, Mary D, Endou H, Wempe MF, Supuran CT, Winum JY, Peyron JF. Co-targeting intracellular pH and essential amino acid uptake cooperates to induce cell death of T-ALL/LL cells. Leuk Lymphoma. 2018 02; 59(2):460-468.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|